Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Xavier C. Badoux, Jacqueline C. Barrientos, Alessandra Tedeschi, Stephen Opat, Ian W. Flinn, Eva Gonzalez Barca, Ryan Jacobs, Edith Szafer-Glusman, Cathy Zhou, Anita Szoke, William G. Wierda, Paolo Ghia, Constantine S. Tam

Blood (2022) 140 (Supplement 1): 224–227.

https://doi.org/10.1182/blood-2022-160338

Published: 2022

Journal Articles

Lymphomagenic Roles of MYC, E2F and Mir-150-5p in Plasmablastic Lymphoma: Therapeutic and Prognostic Implications

Blood (2022) 140 (Supplement 1): 9266–9268.

https://doi.org/10.1182/blood-2022-168552

Published: 2022

Journal Articles

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

Jacob D. Soumerai, Masa Lasica, Stephen Opat, Chan Y. Cheah, Henry Chan, Emma Verner, Eva González Barca, Alessandra Tedeschi, James Hilger, Yiqian Fang, David Simpson, Constantine S. Tam

Blood (2022) 140 (Supplement 1): 9325–9327.

https://doi.org/10.1182/blood-2022-169664

Published: 2022

Journal Articles

Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Angel Serna, Angela Sanchez, Laia Lopez, Juan-Manuel Sancho, Eva Gonzalez Barca, Alberto Lopez-Garcia, Raul Cordoba, Adolfo Jesús Sáez Marín, Ana Isabel Jiminez Ubieto, Ainara Ferrero, Tomas García, Alba Cabirta, M Moraima Jimenez, Lucia Martin, Marta Julia, Sabela Bobillo, Ana Marin-Niebla, Francesc Bosch, Pau Abrisqueta

Blood (2022) 140 (Supplement 1): 9350–9352.

https://doi.org/10.1182/blood-2022-165996

Published: 2022

Journal Articles

Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Blood (2022) 140 (Supplement 1): 9342–9344.

https://doi.org/10.1182/blood-2022-163165

Published: 2022

Journal Articles

Orthotopic Xenografts Models in Relapse/Refractory Lymphomas: A Preclinical Model for Therapeutic, Mechanistic and Functional Studies

Domingo Domenech Eva, Fina Climent, Eva Gonzalez Barca, Eugenia de Lama, Maria Martinez Iniesta, Monica Calaf, Clara Montane, Ana C Oliveira, Patricia Lopez, Gabriela Sanz-Linares, Esmeralda de la Banda, Laura Arregui, Villanueva Alberto, Anna Sureda, Lourdes Farre

Blood (2022) 140 (Supplement 1): 8829–8830.

https://doi.org/10.1182/blood-2022-164848

Published: 2022

Journal Articles

Prospective Assessment of Motor Neurotoxicity and Sarcopenia in CD30+ Lymphoma Patients Treated with Brentuximab Vedotin. Single Center Multidisciplinary Unit Experience

Domingo Domenech Eva, Marta Bellver, German Ferrer, Eva Gonzalez Barca, Itziar Carro, Ana C Oliveira, Patricia Lopez, Gabriela Sanz-Linares, Carmen Aguilera, Montserrat Alemany, Inmaculada Peiro, Anna Sureda, Roser Velasco

Blood (2022) 140 (Supplement 1): 9420–9421.

https://doi.org/10.1182/blood-2022-165345

Published: 2022

Journal Articles

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Paolo Ghia, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Stephen Opat, Ian W. Flinn, Xavier C. Badoux, Alessandra Tedeschi, Eva Gonzalez-Barca, John M. Pagel, Ryan Jacobs, Jacqueline Barrientos, Edith Szafer-Glusman, Cathy Zhou, Joi Ninomoto, James P. Dean, Constantine S. Tam, William G. Wierda

Blood (2021) 138 (Supplement 1): 68.

https://doi.org/10.1182/blood-2021-144544

Published: 2021

Journal Articles

Real Life Experience of Brentuximab Vedotin Plus CHP As First-Line Treatment in CD30 + Peripheral T-Cell Lymphomas

Domingo Domenech Eva, Juan-Manuel Sancho, Eva González-Barca, Nicholas Kelleher, Marta Rodriguez-Luaces, Jordina Rovira Sole, Silvia Verdesoto, Maite Encuentra, Damir Blazevic, Ana C Oliveira, Lourdes Escoda, Josep-Maria Ribera, Anna Sureda

Blood (2021) 138 (Supplement 1): 4543.

https://doi.org/10.1182/blood-2021-149506

Published: 2021

Journal Articles

Preliminary Results from a Phase I Study of HMPL-523, a Selective Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma

Paolo Strati, Dominik Chraniuk, Eva González-Barca, Michal Taszner, Rathi Pillai, Caly Chien, Shivani Nanda, Mark Rudinski, Vijayvel Jayaprakash, Marjo Hahka-Kemppinen, Marek Kania

Blood (2021) 138 (Supplement 1): 2432.

https://doi.org/10.1182/blood-2021-145641

Published: 2021

Journal Articles

Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study

Eva González-Barca, MD PhD, Johannes Duell, MD, Federica Cavallo, Juan-Manuel Sancho, MD PhD, Zsolt Nagy, MD PhD, Pau Abrisqueta, MD PhD, Carlos Panizo, MD PhD, Marinela Augustin, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Kami J. Maddocks, MD, Nagesh Kalakonda, MD, Gilles Salles, MDPhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-140294

Published: 2020

Journal Articles

Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Kami J. Maddocks, MD, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, Anna Marina Liberati, MD, Sven de Vos, MD PhD, Zsolt Nagy, MD PhD, Aleš Obr, MDPhD, Gianluca Gaidano, Pau Abrisqueta, MD PhD, Marc André, MD, Martin Dreyling, MD, Tobias F Menne, MD PhD FRCPath, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Gilles Salles, MDPhD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-140314

Published: 2020

Journal Articles

Impact of a Tailored Nutritional and Physical Exercise Programme on Efficacy and Functional Outcomes in Older Patients with Hematological Malignancies Classified By Frailty Profile

Maite Antonio, MD PhD, Montserrat Arnan Sangerman, MD PhD, Eva Domingo-Domenech, MD, Eva González-Barca, MD PhD, Casimiro Javierre, MD PhD, Laura Hurtos, Judit Sola, Anna Sureda, MD PhD, Josep Maria Borras, MD PhD

Blood (2019) 134 (Supplement_1): 3424.

https://doi.org/10.1182/blood-2019-129908

Published: 2019

Journal Articles

Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Johannes Duell, MD, Kami J. Maddocks, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, MD PhD, Anna Marina Liberati, Sven de Vos, MD PhD, Zsolt Nagy, MD PhD, Aleš Obr, MD PhD, Gianluca Gaidano, MD PhD, Pau Abrisqueta, MD PhD, Marc André, Martin Dreyling, MD, Tobias F Menne, MD PhD FRCPath, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Gilles A. Salles, MD PhD

Blood (2019) 134 (Supplement_1): 1582.

https://doi.org/10.1182/blood-2019-122573

Published: 2019

Journal Articles

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Deborah A. Katz, MD, Michael P. Chu, Kevin A. David, MD, Catherine Thieblemont, MD PhD, Nicholas J. Morley, Sharif S. Khan, Yuqi Chen, James Kalabus, Joan Morris, Abraham Anderson, Ariel A. Avilion, Eva González-Barca, MD PhD

Blood (2019) 134 (Supplement_1): 4077.

https://doi.org/10.1182/blood-2019-121708

Published: 2019

Journal Articles

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Blood (2019) 134 (Supplement_1): 5473.

https://doi.org/10.1182/blood-2019-126588

Published: 2019

Journal Articles

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Blood (2019) 134 (Supplement_1): 4296.

https://doi.org/10.1182/blood-2019-128470

Published: 2019

Journal Articles

Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial

Blood (2019) 134 (Supplement_1): 752.

https://doi.org/10.1182/blood-2019-122191

Published: 2019

Journal Articles

Efficacy of a New Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) in Preclinical Models of B-Cell Lymphoma and Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 5383.

https://doi.org/10.1182/blood-2018-99-111578

Published: 2018

Journal Articles

Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group

Blood (2018) 132 (Supplement 1): 1637.

https://doi.org/10.1182/blood-2018-99-110792

Published: 2018

NARROW

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

Lymphomagenic Roles of MYC, E2F and Mir-150-5p in Plasmablastic Lymphoma: Therapeutic and Prognostic Implications

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Orthotopic Xenografts Models in Relapse/Refractory Lymphomas: A Preclinical Model for Therapeutic, Mechanistic and Functional Studies

Prospective Assessment of Motor Neurotoxicity and Sarcopenia in CD30+ Lymphoma Patients Treated with Brentuximab Vedotin. Single Center Multidisciplinary Unit Experience

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Real Life Experience of Brentuximab Vedotin Plus CHP As First-Line Treatment in CD30 + Peripheral T-Cell Lymphomas

Preliminary Results from a Phase I Study of HMPL-523, a Selective Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma

Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study

Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Impact of a Tailored Nutritional and Physical Exercise Programme on Efficacy and Functional Outcomes in Older Patients with Hematological Malignancies Classified By Frailty Profile

Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial

Efficacy of a New Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) in Preclinical Models of B-Cell Lymphoma and Acute Myeloid Leukemia

Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only